Inclusion Criteria:  Female subject aged >= 18 years Pathologically confirmed malignancy of the cervix or endometrium. Non-epithelial histologies are permitted. Adenocarcinoma in situ is also permitted Patients must be status post hysterectomy for initial management of cervix or endometrial cancer Subject must have non-metastatic disease as determined by clinical exam or computed tomography (CT) or positron emission tomography (PET)/CT imaging Eastern Cooperative Oncology Group (ECOG) performance status =< 2 Recovery to baseline or =< grade 1 Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0 from toxicities related to any prior cancer therapy, unless considered clinically not significant by the treating investigator Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines Life expectancy of > 2 years Chemotherapy can be administered at discretion of the treating radiation, medical, or gynecologic oncologist. Sequential therapy (radiation followed by chemotherapy) is preferred but not required  Exclusion Criteria:  Prior abdominal or pelvic irradiation Interval between the hysterectomy and planned start of radiotherapy exceeding 16 weeks Prior history of inflammatory bowel disease The diagnosis of another malignancy within =< 2 years before study enrollment, except for those considered to be adequately treated with no evidence of disease or symptoms and/or will not require therapy during the study duration (i.e., basal cell or squamous cell skin cancer, carcinoma in situ of the breast, bladder or of the cervix, or low-grade prostate cancer with Gleason score =< 6) Medical, psychiatric, cognitive, or other conditions in the opinion of the investigator that may compromise the subject's ability to understand the subject information, give informed consent, comply with the study protocol or complete the study